PUBLIC HEALTH INSTITUTE OF GEORGIAEnglish · ქართული  |  Verify a certificate →
Professor Irine Datikashvili-Davidi

Professor Irine Datikashvili-Davidi

ირინე დათიკაშვილი-დავიდი

Haematologist

Practice region(s): Tbilisi

English directory information from the existing Georgian record. This information view does not establish licence, credentials or certification.

Original Georgian profile and biography

Listed workplaces

About

Education

2001 - 2005 Georgian State Medical Academy | Department of Hematology and Transfusiology | Academic doctoral degree in medicine.

1994 - 2001 Tbilisi State Medical University | Faculty of General Medicine | Physician.

Work experience

2018 - present Ilia State University | Associate Professor, member of the specialty council.

2018 - present New Vision University | Invited teacher of the hematology course.

2016 - present Caucasus International University | Invited teacher.

2015 - present Tbilisi Medical Academy | Invited teacher.

2010 - present M. Zodelava Hematology Center | Head of the Medical Programs Department; hematologist.

2009 - present Aversi Clinic | Physician, hematologist.

2007 - 2010 GMT College | Invited teacher of the medical-surgical patient management course.

2006 - 2010 Cito Medical Center | Hematologist, consultant.

2005 Hematology - II a 56 | 034534.

2001 - present M. Zodelava Hematology Center | Hematologist.

1994 General physician | 101508.

Certificates, qualifications and training

2020 ICH GCP certificate.

Clinical research

2021 - present Phase 3, multicenter, randomized, open-label study evaluating the efficacy and safety of intravenous efgartigimod (ARGX-113), 10 mg/kg, in adult patients with primary immune thrombocytopenia | Protocol ARGX-113-1803 | Principal investigator.

2020 - present Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of subcutaneous efgartigimod (ARGX-113) PH20 in adult patients with primary immune thrombocytopenia | Protocol ARGX-113-2004.

2020 - present Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of intravenous efgartigimod (ARGX-113), 10 mg/kg, in adult patients with primary immune thrombocytopenia | Protocol ARGX-113-1801 | Principal investigator.

2020 - present Phase 3, multicenter, randomized, double-blind, placebo-controlled study of fostamatinib disodium in patients with warm antibody autoimmune hemolytic anemia | Protocol C-935788-057 | Co-investigator.

2019 - present Randomized, controlled, phase 3 study evaluating pacritinib versus physician's choice in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocytopenia myelofibrosis, with severe thrombocytopenia (platelet count <50,000/µL) | Protocol PAC-303 | Co-investigator.

2019 - present Phase III, randomized, double-blind, parallel-group study comparing the efficacy, safety and immunogenicity of the proposed rituximab biosimilar DRL-RI with MabThera® in previously untreated subjects with stage II-IV, CD20-positive, low-tumor-burden follicular lymphoma | Protocol RI-01-006 | Co-investigator.

2019 - present Phase 2/3, randomized, double-blind, placebo- and active-controlled, parallel-group, multicenter protocol evaluating the efficacy and safety of guselkumab in participants with moderately to severely active Crohn's disease | CNTO1959CRD3001 | Co-investigator.

2019 - present Randomized, double-blind, placebo-controlled, phase 2 study evaluating the effect of filgotinib on semen in adult men with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or non-radiographic axial spondyloarthritis | GLPG0634-CL-227 | Co-investigator.

2019 - 2020 Randomized, double-blind, placebo-controlled, parallel-group, phase 2a study investigating the efficacy, safety, pharmacokinetics and biomarker profiles of CKD-506 in adult subjects with moderate to severe rheumatoid arthritis and an inadequate response to methotrexate | 182RA18009 | Co-investigator.

2018 - 2020 Randomized, double-blind, multicenter, multinational study evaluating the efficacy, safety and immunogenicity of SAIT101 compared with rituximab as first-line immunotherapy in patients with low-grade follicular lymphoma | AGB002 | Co-investigator.

2017 - 2019 Randomized, double-blind study evaluating the efficacy, safety and immunogenicity of ABP 798 compared with rituximab in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL) | 20130109 | Co-investigator.

2015 - present Phase 3, randomized, controlled, open-label study comparing Velcade (bortezomib), melphalan and prednisone (VMP) with daratumumab plus VMP (D-VMP) in previously untreated patients with multiple myeloma who are ineligible for high-dose therapy | 54767414MMY3007 | Co-investigator.

2015 - 2017 Phase 3, randomized, double-blind study comparing PF-05280586 with rituximab as first-line treatment in patients with CD20-positive, low-tumor-burden follicular lymphoma | B3281006 | Co-investigator.

2014 - 2018 Phase 1/3, randomized, parallel-group, active-controlled, double-blind study comparing the pharmacokinetic equivalence and non-inferiority of CT-P10 to rituximab, each administered with cyclophosphamide, vincristine and prednisone, in patients with advanced follicular lymphoma | CT-P10 3.3 | Co-investigator.

2014 - 2018 Evaluation of reduction in the risk of venous thromboembolism after discharge home from hospital in medically ill patients, comparing rivaroxaban with placebo (MARINER study) | RIVAROXDVT3002 | Principal investigator.

2012 - 2015 Phase III, two-stage, international, multicenter, randomized, controlled, open-label study investigating the pharmacokinetics, efficacy and safety of subcutaneous rituximab in combination with CHOP or CVP, compared with intravenous rituximab in combination with CHOP or CVP, in follicular lymphoma, followed by maintenance treatment with subcutaneous or intravenous rituximab | BO22334 | Co-investigator.

2009 - 2017 Phase III, multicenter, randomized, double-blind, placebo-controlled, 3-arm, parallel-treatment study to determine the efficacy and safety of lenalidomide (Revlimid) in combination with melphalan and prednisone versus placebo plus melphalan and prednisone in subjects aged 65 years and older with newly diagnosed multiple myeloma | CC-5013-MM-015 | Co-investigator.

Languages: Georgian, Russian, English.

Contact and sources

© 2026 Certificate.ge · PHIG · Sheni Network